German Court Invalidates Omega-3 Drug Patent

Law360, New York (November 27, 2007, 12:00 AM EST) -- A German patent court has ruled that a patent held by Norwegian pharmaceutical company Pronova BioPharma ASA for the active ingredient in its prescription drug Omacor is invalid, the company said Tuesday.

The drug, which is marketed in the United States as Lovaza, is derived from omega-3 fatty acids and is prescribed for the treatment of very high triglyceride levels in adults. It is the first and only omega-3 derived prescription drug approved by the European Union and the U.S. Food and Drug Administration.

Pronova launched...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.